NCT07182409View on ClinicalTrials.gov

Efficacy and Safety of Monoclonal Antibody in Acute Phase of Neuromyelitis Optica Spectrum Disorder

Not yet recruitingOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
NMOSD
All Listed Sponsors
lead

First Affiliated Hospital of Chongqing Medical University

OTHER

NCT07182409 - Efficacy and Safety of Monoclonal Antibody in Acute Phase of Neuromyelitis Optica Spectrum Disorder | Biotech Hunter | Biotech Hunter